Home | Contact Us | Brochure  | User Guide
0
Username
Password
Forgot Password
Capitaline Newswire App Google Play Capitaline Newswire App Store
02 Apr 2026 00:04 Sensex 73,319.55 185.23 (0.25%) || Nifty 22,713.10 33.70 (0.15%) 00
  AMC
  Single Scheme
  Multi Schemes
  Comparison
  NFO
  Charts
  MF Updates
  Miscellaneous
  Defined Sets
News
Top Equity Holdings by AMC
Interview with Fund Managers Back
26 Aug 2024 09:55
Alembic Pharma gains after receiving USFDA nod for Betamethasone Valerate Foam
Alembic Pharmaceuticals jumped 2.25% to Rs 1,125.35 after the company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium).

Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.

The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.

The pharmaceutical company’s consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.

Powered by Capital Market - Live News
Other Stories
Vikran Engineering bags L...
 (4-Apr  16:12)
Bajaj Housing Finance clo...
 (4-Apr  15:37)
Dabur India expects domes...
 (4-Apr  14:27)
Kernex Microsystems bags ...
 (4-Apr  13:17)
J&K Bank’s gross advances...
 (4-Apr  12:00)
Bajaj Finance Q4 deposits...
 (4-Apr  11:02)
HDFC Bank’s average depos...
 (4-Apr  10:16)
L&T Finance Q4 retail dis...
 (4-Apr  10:01)
Avenue Supermarts Q4 reve...
 (4-Apr  09:00)
RBL Bank's total business...
 (3-Apr  17:34)
  FAQs  |  SEBI  |  AMFI  |  BSE  |  NSE
Glossary  |  Disclaimer   |  Privacy Policy   © Copyright 2022 All rights Reserved. Capital Market Publishers India Pvt. Ltd.